ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 2, 2025 -- For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance, according to a study published online March 29 in The Lancet to coincide with the annual meeting of the American College of Cardiology, held from March 29 to 31 in Chicago.
Marc P. Bonaca, M.D., from the University of Colorado School of Medicine in Aurora, and colleagues conducted a randomized, placebo-controlled trial at 112 outpatient clinical trial sites in 20 countries. Patients were aged 18 years and older and had type 2 diabetes and peripheral artery disease with intermittent claudication. Participants were randomly allocated to receive subcutaneous semaglutide 1.0 mg once per week for 52 weeks or placebo (396 patients in each group).
The researchers found that the estimated median ratio to baseline in maximum walking distance at week 52 was significantly greater in the semaglutide group versus the placebo group (1.21 versus 1.08; estimated treatment ratio, 1.13). Serious adverse events that were possibly or probably related to treatment were reported in five participants (six events) in the semaglutide group and six participants (nine events) in the placebo group; serious gastrointestinal events were the most frequent (two events in two patients in the semaglutide group; five events in three patients in the placebo group). No treatment-related deaths were reported.
"These findings support the use of semaglutide in people with peripheral artery disease and type 2 diabetes and suggest that semaglutide should be prioritized among treatments for this population," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
MONDAY, June 23, 2025 -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist...
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and...
DASH Diet for Diabetes With Low Sodium Reduces BP in Those With Diabetes
WEDNESDAY, June 18, 2025 -- The Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet with lower sodium is tied to clinically meaningful blood pressure reduction in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.